Home Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

FPG #8: Alternative Treatments in Psychiatry
FPG #7: Critical Care in Neurology
Free Medical Books

  Prostate Cancer

  Free Subscription


06.02.2012

3 Anticancer Res
6 BJU Int
2 Cancer
1 Cancer Res
1 Clin Cancer Res
1 Endocrinology
6 Eur Urol
1 Int J Oncol
4 Int J Radiat Oncol Biol Phys
1 Invest Radiol
1 J Magn Reson Imaging
2 J Nucl Med
2 JAMA
1 Nat Rev Urol
1 Oncogene
1 Prog Urol
8 Prostate
1 Semin Oncol
1 Ther Adv Urol
2 Urol Int


   Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Anticancer Res


  1. After prostate cancer.
    Anticancer Res. 2012;32:718.
    PubMed     Text format     Related articles   



  2. Prostate cancer.
    Anticancer Res. 2012;32:718.
    PubMed     Text format     Related articles   


  3. SCHALLIER D , Decoster L, Braeckman J, Fontaine C, et al
    Docetaxel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC): an Observational Study in a Single Institution.
    Anticancer Res. 2012;32:633-41.
    PubMed     Text format     Related articles    Abstract available



    BJU Int

  4. CARTER HB
    PROSTATE-SPECIFIC ANTIGEN VELOCITY (PSAV) RISK COUNT IMPROVES THE SPECIFICITY OF SCREENING FOR CLINICALLY SIGNIFICANT PROSTATE CANCER.
    BJU Int. 2012 Feb 1. doi: 10.1111/j.1464-410X.2011.10908.
    PubMed     Text format     Related articles   


  5. LOEB S , Metter EJ, Kan D, Roehl KA, et al
    Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.
    BJU Int. 2012 Feb 1. doi: 10.1111/j.1464-410X.2011.10900.
    PubMed     Text format     Related articles    Abstract available


  6. ROSS AE , Feng Z, Pierorazio PM, Landis P, et al
    Effect of treatment with 5-alpha reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
    BJU Int. 2012 Jan 30. doi: 10.1111/j.1464-410X.2011.10875.
    PubMed     Text format     Related articles    Abstract available


  7. VAN LEEUWEN PJ , Otto SJ, Kranse R, Roobol MJ, et al
    Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.
    BJU Int. 2012 Jan 30. doi: 10.1111/j.1464-410X.2011.10811.
    PubMed     Text format     Related articles    Abstract available


  8. ANTONARAKIS ES , Feng Z, Trock BJ, Humphreys EB, et al
    The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.
    BJU Int. 2012;109:32-9.
    PubMed     Text format     Related articles    Abstract available


  9. DONOVAN MJ , Khan FM, Powell D, Bayer-Zubek V, et al
    Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery.
    BJU Int. 2012;109:40-5.
    PubMed     Text format     Related articles    Abstract available



    Cancer

  10. ROSS RW , Galsky MD, Febbo P, Barry M, et al
    Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer : A Prostate Cancer Clinical Trials Consortium trial.
    Cancer. 2012 Jan 26. doi: 10.1002/cncr.27416.
    PubMed     Text format     Related articles    Abstract available


  11. ZAFARANA G , Ishkanian AS, Malloff CA, Locke JA, et al
    Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy.
    Cancer. 2012 Jan 26. doi: 10.1002/cncr.26729.
    PubMed     Text format     Related articles    Abstract available



    Cancer Res

  12. LESSARD L , Labbe DP, Deblois G, Begin LR, et al
    PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer.
    Cancer Res. 2012.
    PubMed     Text format     Related articles    Abstract available



    Clin Cancer Res

  13. WAN X , Liu J, Lu JF, Tzelepi V, et al
    Activation of beta-Catenin Signaling in Androgen Receptor-Negative Prostate Cancer Cells.
    Clin Cancer Res. 2012;18:726-36.
    PubMed     Text format     Related articles    Abstract available



    Endocrinology

  14. COSS CC , Jones A, Parke DN, Narayanan R, et al
    Preclinical Characterization of a Novel Diphenyl Benzamide Selective ERalpha Agonist for Hormone Therapy in Prostate Cancer.
    Endocrinology. 2012.
    PubMed     Text format     Related articles    Abstract available



    Eur Urol

  15. OELKE M
    Re: dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the reduction by dutasteride of prostate cancer events trial.
    Eur Urol. 2012;61:624-5.
    PubMed     Text format     Related articles   


  16. MOYAD MA
    Re: a prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
    Eur Urol. 2012;61:623-4.
    PubMed     Text format     Related articles   


  17. SCHELLHAMMER P
    Re: prediction of erectile function following treatment for prostate cancer.
    Eur Urol. 2012;61:622.
    PubMed     Text format     Related articles   


  18. DELONGCHAMPS NB , Zerbib M
    Re: role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection.
    Eur Urol. 2012;61:622-3.
    PubMed     Text format     Related articles   


  19. KWIATKOWSKI M , Klotz L, Hugosson J, Recker F, et al
    Comment on the US Preventive Services Task Force's Draft Recommendation on Screening for Prostate Cancer.
    Eur Urol. 2012.
    PubMed     Text format     Related articles   


  20. CHADE DC , Eastham J, Graefen M, Hu JC, et al
    Cancer Control and Functional Outcomes of Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Systematic Review of the Literature.
    Eur Urol. 2012.
    PubMed     Text format     Related articles    Abstract available



    Int J Oncol

  21. JIANG J , Loganathan J, Eliaz I, Terry C, et al
    ProstaCaid inhibits tumor growth in a xenograft model of human prostate cancer.
    Int J Oncol. 2012 Jan 24. doi: 10.3892/ijo.2012.1344.
    PubMed     Text format     Related articles    Abstract available



    Int J Radiat Oncol Biol Phys

  22. ALUWINI S , van Rooij PH, Kirkels WJ, Jansen PP, et al
    High-Dose-Rate Brachytherapy and External-Beam Radiotherapy for Hormone-Naive Low- and Intermediate-Risk Prostate Cancer: A 7-Year Experience.
    Int J Radiat Oncol Biol Phys. 2012.
    PubMed     Text format     Related articles    Abstract available


  23. MARTINEZ-MONGE R , Moreno M, Ciervide R, Cambeiro M, et al
    External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.
    Int J Radiat Oncol Biol Phys. 2012;82:e469-76.
    PubMed     Text format     Related articles    Abstract available


  24. CHOPRA S , Toi A, Taback N, Evans A, et al
    Pathological predictors for site of local recurrence after radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys. 2012;82:e441-8.
    PubMed     Text format     Related articles    Abstract available


  25. AL-UBAIDI FL , Schultz N, Egevad L, Granfors T, et al
    Castration Therapy of Prostate Cancer Results in Downregulation of HIF-1alpha Levels.
    Int J Radiat Oncol Biol Phys. 2012;82:1243-8.
    PubMed     Text format     Related articles    Abstract available



    Invest Radiol

  26. SOMFORD DM , Hambrock T, Hulsbergen-van de Kaa CA, Futterer JJ, et al
    Initial Experience With Identifying High-Grade Prostate Cancer Using Diffusion-Weighted MR Imaging (DWI) in Patients With a Gleason Score </=3 + 3 = 6 Upon Schematic TRUS-Guided Biopsy: A Radical Prostatectomy Correlated Series.
    Invest Radiol. 2012.
    PubMed     Text format     Related articles    Abstract available



    J Magn Reson Imaging

  27. FAN X , Haney CR, Agrawal G, Pelizzari CA, et al
    High-resolution MRI of excised human prostate specimens acquired with 9.4T in detection and identification of cancers: Validation of a technique.
    J Magn Reson Imaging. 2011;34:956-61.
    PubMed     Text format     Related articles    Abstract available



    J Nucl Med

  28. DELSO G , Furst S, Jakoby B, Ladebeck R, et al
    Performance Measurements of the Siemens mMR Integrated Whole-Body PET/MR Scanner.
    J Nucl Med. 2011.
    PubMed     Text format     Related articles    Abstract available


  29. ABIRAJ K , Mansi R, Tamma ML, Fani M, et al
    Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.
    J Nucl Med. 2011;52:1970-8.
    PubMed     Text format     Related articles    Abstract available



    JAMA

  30. HOSKOTE SS , Nadkarni GN, Fried ED
    Prostate cancer risk and vitamin E.
    JAMA. 2012;307:454.
    PubMed     Text format     Related articles   


  31. GABY AR
    Prostate cancer risk and vitamin E.
    JAMA. 2012;307:453-4.
    PubMed     Text format     Related articles   



    Nat Rev Urol

  32. MOUL JW
    Prostate cancer: Making the switch from LHRH antagonist to LHRH agonist.
    Nat Rev Urol. 2012 Jan 31. doi: 10.1038/nrurol.2012.
    PubMed     Text format     Related articles   



    Oncogene

  33. THOBE MN , Gray JK, Gurusamy D, Paluch AM, et al
    The Ron receptor promotes prostate tumor growth in the TRAMP mouse model.
    Oncogene. 2011;30:4990-8.
    PubMed     Text format     Related articles    Abstract available



    Prog Urol

  34. BARRY DELONGCHAMPS N , Peyromaure M, Kpatcha F, Beuvon F, et al
    [pT3N0 prostate cancer treated with radical prostatectomy as sole treatment: Oncological results and predictive factors of recurrence].
    Prog Urol. 2012;22:100-5.
    PubMed     Text format     Related articles    Abstract available



    Prostate

  35. SHEN J , Hruby GW, McKiernan JM, Gurvich I, et al
    Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer.
    Prostate. 2012 Feb 1. doi: 10.1002/pros.22499.
    PubMed     Text format     Related articles    Abstract available


  36. CHEN ZH , Zhang GL, Li HR, Luo JD, et al
    A panel of five circulating microRNAs as potential biomarkers for prostate cancer.
    Prostate. 2012 Feb 1. doi: 10.1002/pros.22495.
    PubMed     Text format     Related articles    Abstract available


  37. KAINI RR , Sillerud LO, Zhaorigetu S, Hu CA, et al
    Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate cancer cells.
    Prostate. 2012 Jan 31. doi: 10.1002/pros.22489.
    PubMed     Text format     Related articles    Abstract available


  38. FANG Y , Qiu Q, Domarkas J, Larroque-Lombard AL, et al
    "Combi-targeting" mitozolomide: Conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer.
    Prostate. 2012 Jan 30. doi: 10.1002/pros.22475.
    PubMed     Text format     Related articles    Abstract available


  39. TSUI KH , Chang YL, Feng TH, Chang PL, et al
    Glycoprotein transmembrane nmb: An androgen-downregulated gene attenuates cell invasion and tumorigenesis in prostate carcinoma cells.
    Prostate. 2012 Jan 30. doi: 10.1002/pros.22494.
    PubMed     Text format     Related articles    Abstract available


  40. YAO K , Youn H, Gao X, Huang B, et al
    Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells.
    Prostate. 2012 Jan 30. doi: 10.1002/pros.22493.
    PubMed     Text format     Related articles    Abstract available


  41. IDE H , Lu Y, Yu J, China T, et al
    Testosterone promotes DNA damage response under oxidative stress in prostate cancer cell lines.
    Prostate. 2012 Jan 30. doi: 10.1002/pros.22492.
    PubMed     Text format     Related articles    Abstract available


  42. JENNBACKEN K , Welen K, Olsson A, Axelsson B, et al
    Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
    Prostate. 2011 Oct 5. doi: 10.1002/pros.21495.
    PubMed     Text format     Related articles    Abstract available



    Semin Oncol

  43. BEACH DF , Somer RA, Hoffman-Censits J, Lin J, et al
    A wealth of new options: a case presentation of the management of castration-recurrent prostate cancer.
    Semin Oncol. 2012;39:1-8.
    PubMed     Text format     Related articles   



    Ther Adv Urol

  44. OSANTO S , Van Poppel H
    Emerging novel therapies for advanced prostate cancer.
    Ther Adv Urol. 2012;4:3-12.
    PubMed     Text format     Related articles    Abstract available



    Urol Int

  45. PINTO F , Totaro A, Palermo G, Calarco A, et al
    Imaging in Prostate Cancer Staging: Present Role and Future Perspectives.
    Urol Int. 2012.
    PubMed     Text format     Related articles    Abstract available


  46. PHILIPPOU P , Yap T, Chinegwundoh F
    Third-Generation Salvage Cryotherapy for Radiorecurrent Prostate Cancer: A Centre's Experience.
    Urol Int. 2012.
    PubMed     Text format     Related articles    Abstract available



Thank you for your interest in scientific medicine.


Amedeo is a Flying Publisher website.

   Design: